Congestive Heart Failure
Conditions
Keywords
Pantoprazole, congestive heart failure
Brief summary
Recently literature revealed facts, that show H+/K+ ATPase expression is not limited tot he stomach. H+/K+ ATPase was also found in smooth muscle cells and in other tissues (McCabe, R.D. et al., Am J Physiol. 1992). For myocard a localisation is only proven for rats yet (Beisvag, V. et al., Acta Physiol Scand. 2003). Moreover biochemical hints lead us to a highly probability of a myocardial H+/K+ ATPase (Nagashima, R. et al., Jpn Heart J. 1999).
Detailed description
Recently literature revealed facts, that show H+/K+ ATPase expression is not limited tot he stomach. H+/K+ ATPase was also found in smooth muscle cells and in other tissues (McCabe, R.D. et al., Am J Physiol. 1992). For myocard a localisation is only proven for rats yet (Beisvag, V. et al., Acta Physiol Scand. 2003). Moreover biochemical hints lead us to a highly probability of a myocardial H+/K+ ATPase (Nagashima, R. et al., Jpn Heart J. 1999). Aim of our clinical study is to examine, whether proton pump inhibitors have an influence on myocardial contraction of human myocard and we want to ascertain the amount of influence of a H+/K+ ATPase on myocardial contraction. Therefore the mechanism of a putative inhibition by proton pump inhibitors is at our focus. These findings will be of major credit regarding treatment of patients with congestive heart failure with common proton pump inhibitors. We want to find out, whether this intake may have a negative inotropic effect on the heart failure myocard.
Interventions
DRUGPantoprazole
Pantoprazole 160 mg I.V.
Sponsors
Johann Wolfgang Goethe University Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Only patients older than 18 years. Range 18 to 80 years 2. Only cooperative patients 3. Only patients with a need for a coronary angiography, independently from our study 4. Only patients with a left ventricular ejection fraction as demanded in the study protocol 5. Only patients with clinical symptoms of congestive heart failure, corresponding to New York Heart Association stage NYHA II or III 6. Only patients without oral or i.v. application of a proton pump inhibitor up to 48 hours prior to the study catheterization
Exclusion criteria
1. Manifest or severe accompanying diseases, despite of diabetes mellitus 2. Intravascular or oral application of proton pump inhibitors within the last 48 hours 3. Intake of Metformin within the last 24 hours 4. Status post heart transplant 5. Pregnancy 6. Known intolerance of pantoprazole 7. severe side effects of the tested substance pantoprazole, as well as pharmacokinetic interactions through CYP isoenzymes 8. Existance of side effects as given in the pantoprazole drug information, among others disturbances of blood- and lymphatic system, leukopenia, thrombopenia, affections of gastrointestinal tract, nerve system affections, psychiatric affections, renal or bladder affections 9. Participation in a other clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Aim of our clinical study is to examine, whether proton pump inhibitors have an influence on myocardial contraction of human myocard and we want to ascertain the amount of influence of a H+/K+ ATPase on myocardial contraction. | 6 months |
Countries
Germany
Outcome results
None listed